Proposed score for survival of patients with myelodysplastic syndromes

European Journal of Clinical Investigation

Volumn 43, Issue 11, 2013, Pages 1120-1128

  Sperr, Wolfgang R ^a   Kundi, Michael ^a   Wimazal, Friedrich ^b   Nösslinger, Thomas ^c   Schönmetzler Makrai, Anabel ^c   Stauder, Reinhard ^d   Krieger, Otto ^e   Neukirchen, Judith ^f   Germing, Ulrich ^f   Pfeilstöcker, Michael ^a,c   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c Hanusch Hospital   (Australia)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Hospital of the Elisabethinen Linz   (Australia)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Age; Comorbidity; Ferritin; International prognostic scoring system; Myelodysplastic syndromes; Survival

Indexed keywords

FERRITIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; COMORBIDITY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENTERITIS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFE EXPECTANCY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OBESITY; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; SURVIVAL PREDICTION; VALIDATION STUDY; ADOLESCENT; AUSTRIA; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; PROGNOSIS; YOUNG ADULT;

EID: 84885429749     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12149     Document Type: Article

References (40)

1. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011;35:1591-6.
2. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-36.
3. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008;87:691-9.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 1994;87:746-54.
6. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001: pp 62-73.
7. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press Lyon; 2008: pp 88-103.
8. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005;32:S3-10.
9. Greenberg PL. Risk factors and their relationship to the prognosis of myelodysplastic syndromes. Leuk Res 1998;22:S3-6.
10. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-9.
11. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia 1994;8:1906-13.
12. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-33.
13. Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabadella M, García S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
14. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia 1993;7:1315-23.
15. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H et al. Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia 1993;7:499-508.
16. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
17. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
18. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;12:1596-604.
19. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010;21:120-5.
20. Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 2008;9:927-34.
21. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010;21:114-9.
22. Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009;94:729-32.
23. Breccia M, Federico V, Latagliata R, Mercanti C, D'Elia GM, Cannella L et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res 2011;35:159-62.
24. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-9.
25. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011;29:2240-46.
26. Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 2008;38:143-9.
27. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007;S3:10-5.
28. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A et al. Deferasirox in iron overloaded patients with transfusion dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010;34:557-66.
29. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;109:2912-19.
30. Pfeilstöcker M, Reisner R, Nösslinger T, Grüner H, Nowotny H, Tüchler H et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999;106:455-63.
31. Wimazal F, Sperr WR, Kundi M, Vales A, Fonatsch C, Thalhammer-Scherrer R et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001;80:272-77.
32. Müller-Berndorff H, Haas PS, Kunzmann R, Schulte-Mönting J, Lübbert M. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol 2006;85:502-13.
33. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
34. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538-43.
35. Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005;19:2223-31.
36. Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009;33:1469-74.
37. Várkonyi J, Tarkovács G, Karádi I, Andrikovics H, Varga F, Varga F et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003;109:64-7.
38. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008;111:1067-77.
39. Ogata K. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 2008;26:193-8.
40. Della Porta MG, Ambaglio I, Ubezio M, Travaglino E, Pascutto C, Malcovati L. Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. Haematologica 2012;97:631-2.